The role of microbiota in esophageal squamous cell carcinoma: A review of the literature
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Hsueh-Chien Chiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Microbiota. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cheng Kung University Hospital.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) exhibits high incidence with poor prognosis. Alcohol drinking, cigarette smoking, and betel nut chewing are well‐known risk factors. Dysbiosis, an imbalance of the microbiota residing in a local environment, is known to be associated with human diseases, especially cancer. This article reviews the current evidence of esophageal microbiota in ESCC carcinogenesis, including initiation, progression, and drug resistance. Articles involving the esophageal microbiota, diagnosis, treatment, and the progression of esophageal cancer were acquired using a comprehensive literature search in PubMed in recent 10 years. Based on 16S rRNA sequencing of human samples, cell, and animal studies, current evidence suggests dysbiosis of the esophagus promotes ESCC progression and chemotherapy resistance, leading to a poor prognosis. Smoking and drinking are associated with esophageal dysbiosis. Specific bacteria have been reported to promote carcinogenesis, involving either progression or drug resistance in ESCC, for example Porphyromonas gingivalis and Fusobacterium nucleatum . These bacteria promote ESCC cell proliferation and migration via the TLR4/NF‐κB and IL‐6/STAT3 pathways. F. nucleatum induces cisplatin resistance via the enrichment of immunosuppressive myeloid‐derived suppressor cells (MDSCs). Correcting the dysbiosis and reducing the abundance of specific esophageal pathogens may help in suppressing cancer progression. In conclusion, esophageal dysbiosis is associated with ESCC progression and chemoresistance. Screening the oral and esophageal microbiota is a potential diagnostic tool for predicting ESCC development or drug‐resistance. Repairing esophageal dysbiosis is a novel treatment for ESCC. Clinical trials with probiotics in addition to current chemotherapy are warranted to study the therapeutic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- International Center for Wound Repair and Regeneration (iWRR), College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Hsueh-Chien Chiang, Wei-Lun Chang
Förderung
- National Cheng Kung University Hospital
Zitieren
APA
Chiang, H. C., Hughes, M., & Chang, W. L. (2023). The role of microbiota in esophageal squamous cell carcinoma: A review of the literature. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15096
Vancouver
Chiang HC, Hughes M, Chang WL. The role of microbiota in esophageal squamous cell carcinoma: A review of the literature. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15096
BibTeX
@article{Chiang2023,
author = {Chiang, Hsueh-Chien and Hughes, Michael and Chang, Wei-Lun},
title = {The role of microbiota in esophageal squamous cell carcinoma: A review of the literature},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15096}
}
EUVIMED